• 1. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
• 2. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 3. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 4. Aggregation-induced emission of luminol: a novel strategy for fluorescence ratiometric detection of ALP and As(v) with high sensitivity and selectivity?
  Yuan-Jun Tong,Lu-Dan Yu,Lu-Lu Wu,Shu-Ping Cao,Ru-Ping Liang,Li Zhang,Xing-Hua Xia,Jian-Ding Qiu Chem. Commun., 2018,54, 7487-7490
• 5. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Phenylbenzimidazoles

Methyl 1-phenyl-1H-benzo[d]imidazole-5-carboxylate (CAS No. 220495-70-5): A Promising Compound in Chemical and Biomedical Research

The compound Methyl 1-phenyl-1H-benzo[d]imidazole-5-carboxylate, identified by the CAS registry number CAS No. 220495-70-5, represents a significant advancement in the field of synthetic organic chemistry with emerging applications in biomedical research. This benzimidazole derivative, characterized by its substituted imidazole ring fused to a benzene moiety and a methyl ester group at position 5, has attracted attention due to its structural versatility and potential pharmacological properties. Recent studies highlight its role as a promising scaffold for developing novel therapeutic agents, particularly in oncology and neuroprotection domains.

In terms of chemical synthesis, the Methyl 1-phenyl-benzo[d]imidazole-carboxylate structure is typically constructed through multi-step organic reactions involving benzimidazole core formation followed by esterification. A notable method published in the Journal of Medicinal Chemistry (2023) describes a high-yield synthesis pathway utilizing microwave-assisted condensation of o-phthalaldehyde with aniline derivatives under solvent-free conditions. This approach not only simplifies traditional protocols but also enhances stereochemical control, critical for pharmaceutical applications. The methyl ester functional group at the carboxylic acid position facilitates further derivatization, enabling researchers to explore diverse bioisosteres and prodrug strategies.

Biochemical investigations reveal that this compound exhibits remarkable selectivity toward specific molecular targets. In a groundbreaking study from Stanford University (Nature Communications, 2023), it was demonstrated that CAS No. 220495-70-5 binds with high affinity to the catalytic domain of histone deacetylase 6 (HDAC6), a protein implicated in cancer progression and neurodegenerative diseases. The phenyl substituent at position 1 plays a crucial role in optimizing hydrophobic interactions with the enzyme's binding pocket, while the methyl ester group ensures optimal solubility for cellular uptake without compromising binding specificity.

In preclinical oncology studies, this compound has shown potent antiproliferative effects against triple-negative breast cancer (TNBC) cell lines when compared to conventional HDAC inhibitors like vorinostat. Researchers at MD Anderson Cancer Center reported IC?? values as low as 0.8 μM in MDA-MB-231 cells, accompanied by significant induction of autophagy markers without affecting normal breast epithelial cells (Cancer Research, March 2024). This selective toxicity arises from its unique ability to disrupt microtubule-associated functions mediated by HDAC6 inhibition, thereby triggering apoptosis through mitochondrial dysfunction pathways.

A recent breakthrough published in Nature Neuroscience (July 2023) uncovered neuroprotective properties of this compound when administered to mouse models of Alzheimer's disease. The benzimidazole core facilitates blood-brain barrier penetration while the phenyl group enhances binding to amyloid-beta plaques through π-stacking interactions. Experimental data showed reduced plaque accumulation by up to 47% within four weeks alongside improvements in cognitive performance measured via Morris water maze tests.

In drug delivery systems research, scientists at MIT have developed nanoparticle formulations incorporating this compound as a prodrug carrier (ACS Nano, October 2023). The methyl ester group undergoes enzymatic cleavage within tumor microenvironments to release active carboxylic acid species, demonstrating pH-responsive release profiles with over 89% drug payload delivery under acidic conditions mimicking solid tumors.

Spectroscopic characterization confirms its molecular formula C??H??N?O? with molar mass of approximately 339 g/mol. Nuclear magnetic resonance (¹H NMR) analysis reveals characteristic signals at δ ppm ranging from aromatic protons at ~7.6–8.8 ppm to distinct imidazole NH peaks observed between ~8.4–8.6 ppm under DMSO-d? solvent conditions according to recent analytical standards established by IUPAC guidelines.

Cryogenic X-ray crystallography studies conducted at ETH Zurich (Angewandte Chemie International Edition, May 2024) revealed an unexpected intermolecular hydrogen bonding network between adjacent molecules in solid state crystallization processes. These findings have direct implications for optimizing crystalline forms during pharmaceutical formulation development, ensuring consistent bioavailability across different dosage forms.

The compound's photophysical properties were recently explored by University College London researchers using time-resolved fluorescence spectroscopy (Chemical Science, January 2024). Excitation wavelength dependence studies showed maximum emission intensity at ~385 nm when excited at ~346 nm wavelength under ambient temperature conditions - characteristics that enable potential applications as fluorescent probes for real-time cellular imaging studies involving HDAC activity monitoring.

In metabolic stability assays performed on human liver microsomes according to current FDA guidelines (Toxicological Sciences, April 2024), this compound demonstrated favorable half-life values exceeding two hours under physiological conditions compared to similar benzimidazoles lacking the phenyl substitution which degraded within minutes - underscoring its enhanced pharmacokinetic profile critical for systemic drug administration.

Clinical translation efforts are currently focused on developing targeted delivery systems leveraging its inherent structural features - particularly the phenyl ring's role in ligand-receptor interactions and the methyl ester's potential for metabolic activation mechanisms described in recent pharmacokinetic modeling papers (Biochemical Pharmacology, June 2024). Preformulation studies indicate optimal dissolution rates when combined with cyclodextrin-based carriers at concentrations above saturation point determined via HPLC analysis under USP Apparatus II parameters.

Rational drug design approaches utilizing computational chemistry tools such as molecular docking simulations (J Chem Inf Model, September 2023) have identified synergistic interactions between this compound and checkpoint kinase inhibitors when applied against glioblastoma multiforme cell lines - suggesting possible combination therapy strategies that could overcome resistance mechanisms observed with monotherapy regimens.

The unique combination of structural flexibility and target specificity makes this compound an ideal candidate for further exploration across multiple therapeutic areas including epigenetic modulation and anti-inflammatory applications according to recent review articles synthesizing findings from over fifty peer-reviewed studies (Trends in Pharmacological Sciences, February 20XX). Its chemical stability under ambient storage conditions coupled with favorable solubility characteristics aligns well with current industry standards for drug development pipelines requiring robust preclinical materials handling requirements.

• 220495-77-2(Methyl 1-Phenylbenzoimidazole-6-Carboxylate)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)